Dr. Villaflor on RAVD of Radiotherapy With Induction Chemotherapy in HNSCC
July 21st 2015Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.
Dr. Nanda on Immunotherapy in Metastatic TNBC
July 18th 2015Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.
Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO
June 25th 2015OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.
Obama Signs SGR Repeal, Heralding New Era in Medicare Reimbursement
With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.
Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma
March 25th 2015OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.
Will Immuno-oncology Become the Backbone of Treatment for all Cancers?
February 13th 2015With the proliferation of agents for cancer over the past few years, including both targeted and immunotherapies, the number of clinical questions surround- ing optimal sequencing and combinations approaches infinity.
Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial
June 17th 2014Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Dr. Vokes on HPV-Related Head and Neck Cancer
August 29th 2013Everett E. Vokes, MD, Giant of Cancer Care in the Head and Neck Cancer Category, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses HPV-related head and neck cancer